|
Sections
Agriculture
Applied sciences
Arts
Belief
Business
Chronology
Culture
Education
Environment
Geography
Health
History
Humanities
Language
Law
Life
Mathematics
Nature
People
Politics
Science
Society
Technology
|
Amylin Pharmaceuticals is a biopharmaceutical company based in San Diego, CA, that was founded in 1987. The company is engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. Currently, Amylin produces three drugs, Symlin (pramlintide acetate) and Byetta (exenatide) and Bydureon (exenatide extended-release). Amylin also is working on producing analog of human leptin, metreleptin.[4]
In July 2012, Bristol-Myers Squibb announced it would acquire Amylin Pharmaceuticals for $5.3 billion.[5]
References [edit]
External links [edit]
 Amylin Pharmaceuticals Increases Speed to Insight with 100 Million Rows Amylin Pharmaceuticals is a bio-pharmaceutical company dedicated to improving lives by discovering, developing and commercializing innovative medicines. It's... |  Carl Icahn Files Suit Against Amylin Pharmaceuticals Carl Icahn filed a complaint in Delaware against Amylin Pharmaceuticals (NASDAQ:AMLN) that seeks the extension of the board nomination deadline, and if succe... |  Chris Allbritain from Amylin Pharmaceuticals discusses sharedserviceslink.com events Video testimonial from Chris Allbritain, Associate Director Strategic Sourcing/Procurement at Amylin Pharmaceuticals speaking about sharedserviceslink.com's ... |  Amylin Pharmaceuticals Reports Narrower-Than-Expected Loss (AMLN) 4-26-12-Amylin Pharmaceuticals (NASDAQ:AMLN) reported a Q1 loss of $0.23, topping estimates by $0.04. Revenues in the quarter were flat at $153.7 million, mi... |  Amylin Pharmaceuticals Shares Rise After Rejecting Bid by Bristol-Myers Squibb Shares of Amylin Pharmaceuticals (NASDAQ:AMLN) rose 48% to $22.81 in morning trading after Bloomberg reported the company rejected a bid from Bristol-Myers S... |  Amylin Pharmaceuticals Reports Mixed Q2 Earnings Amylin Pharmaceuticals (NASDAQ:AMLN) reported Q2 loss of $0.21 per share, wider than analyst estimate loss of $0.18. Revenues for the quarter rose 2.1% to $1... |  Morgan Stanley Said UW Rating On Amylin Pharma Was Based On Bydureon Launch Concerns Morgan Stanley analysts said their underweight rating on Amylin Pharmaceuticals (NASDAQ:AMLN) was based on their expectations that the Bydureon launch was go... |  Shares of Amylin Pharmaceuticals, Inc. Tumble Over 50% Following Downgrade to Neutral Shares of Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) fell 51% earlier Wednesday to $10.10 after the company was downgraded from Overweight to Neutral at JP M... |  Thinking Differently to Enable Change and a More Virtual Organization 5th Annual HIMSS So. Cal./CHIEF CIO Forum Steve Phillpott, CIO, Amylin Pharmaceuticals. |  AstraZeneca PLEASE SET THE BEAGLES FREE NOW ! PLEASE SIGN & SHARE WIDELY AND URGENTLY THESE 3 PETITIONS ➨ ▻1 https://www.change.org/petitions/astrazeneca-please-set-the-beagles-free ▻2http://action.peta.... |
| |
U-T San Diego
Tue, 21 May 2013 04:10:37 -0700
Byetta is a best-selling drug developed by San Diego-based Amylin Pharmaceuticals, which was bought last year by Bristol-Myers Squibb. The New York-based pharmaceutical giant is closing Amylin's San Diego operations, a process due to be completed by ...
| | |
Wall Street Journal (press release)
Thu, 16 May 2013 05:11:17 -0700
Michael Abrashoff, Former Navy Commander and Author -- Brian Baker, VP of Finance, Cleave Biosciences -- Robert Baltera, Former CEO, Amira Pharmaceuticals, Inc. -- Daniel Bradbury, Former CEO, Amylin Pharmaceuticals, Inc. -- David Conway, ...
| | |
Seeking Alpha
Sun, 19 May 2013 13:55:33 -0700
As early as 2007, the FDA began hearing reports of pancreatitis from doctors prescribing Byetta, a popular injectable GLP-1 agonist marketed by Bristol-Myers Squibb (BMY) and originally developed by Amylin Pharmaceuticals. Two years later Merck & Co's ...
| | |
DC Progressive
Wed, 08 May 2013 18:29:38 -0700
Bristol-Myers Squibb has agreed to buy Amylin Pharmaceuticals in a deal valued at nearly $7 billion. Bristol-Myers will pay $31 a share in cash for Amylin under the terms of the deal. Bristol-Myers will also assume Amylin's debt as part of the deal and ...
| ![]() PR Web (press release) |
PR Web (press release)
Mon, 13 May 2013 14:37:22 -0700
On May 9 a woman filed a lawsuit against drug makers Amylin Pharmaceuticals and Eli Lilly in federal court, alleging that the companies failed to adequately warn her about type 2 diabetes drug Byetta's link to thyroid cancer, according to court ...
| | |
Wall Street Journal (press release)
Mon, 29 Apr 2013 05:09:24 -0700
Michael Abrashoff, Former Navy Commander and Author -- Brian Baker, Senior Finance Consultant, Cleave Biosciences -- Robert Baltera, Former CEO, Amira Pharmaceuticals, Inc. -- Daniel Bradbury, Former CEO, Amylin Pharmaceuticals, Inc. -- David ...
| | |
Ring of Fire
Wed, 08 May 2013 15:10:13 -0700
With the FDA needing to review the threats that these drugs pose to patients, it seems to imply that the companies: Amylin Pharmaceuticals, Merck & Co., and Novo Nordisk Inc. (Victoza), were in a rush to get their products approved for sale without ...
| ![]() Medscape |
Medscape
Wed, 08 May 2013 09:33:21 -0700
For example, the first GLP-1-based therapy, exenatide (Bydureon, Lilly/Amylin Pharmaceuticals), was launched in the United States in 2005, and a single case of acute pancreatitis was reported in 2006. However, by the second quarter of 2012, US Food and ...
|
Oops, we seem to be having trouble contacting Twitter
|
|
You can talk about Amylin Pharmaceuticals with people all over the world in our discussions.
|
US$758M (FY 2009)[2]
US$-173M (FY 2009)[2]
